Welcome to C4 Therapeutics

C4 Therapeutics is harnessing the innate power of the body to control the quality of proteins within cells.  Our approach uses drugs to target disease-causing proteins for destruction.  This breakthrough technology offers many advantages for the treatment of cancer and other diseases, while avoiding traditional drug resistance.

Latest News

The Boston Globe Names C4 Therapeutics A Top Place to Work for 2017

blue circlesCAMBRIDGE, MA November 17, 2017 - C4 Therapeutics (C4T) has been named one of the Top Places to Work in Massachusetts in the 10th annual employee-based survey project from The Boston Globe.

Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best – their employees. The survey measures employee opinions about their company's direction, execution, management, pay and benefits, and engagement. The employers are placed into one of four groups: small, with 50 to 99 employees; medium, with 100 to 249 workers; large, with 250 to 999; and largest, with 1,000 or more.  read more...


C4 Therapeutics Appoints Ron Kaiser as Chief Financial Officer

blue circlesCAMBRIDGE, MA November 14, 2017 - C4 Therapeutics (C4T)  Ron brings to C4 Therapeutics over 35 years of executive and financial management experience, serving as a Director, CEO and CFO for public companies and venture-backed portfolio companies in the technology and life sciences industries including Sucampo Pharmaceuticals, OTG Software, Trusted Information Systems, Charmilles Technology Manufacturing Corporation, Leeco Diagnostics, Inc., Somanetics Corporation, and Photon Sources, Inc.  Ron is a Certified Board Leadership Fellow of the National Association of Corporate Directors (NACD) and holds dual BA degrees in accounting and multi-disciplinary pre-law from Michigan State University.  read more... 

C4 Therapeutics Appoints Michael Kim as VP of Business Development

blue circles

CAMBRIDGE, Mass. August 11, 2017 C4 Therapeutics (C4T) today announced the appointment of Michael Kim, Ph.D., as Vice President of Business Development. Dr. Kim comes to C4 Therapeutics from ARIAD Pharmaceuticals where he held responsibilities for partnering activities around early and late stage programs in addition to portfolio strategy and alliance management. He started his business career as a strategy consultant with Leerink Swann and Company and progressed to Corporate Strategy and Business Development roles of increasing responsibility at Alkermes, Vertex Pharmaceuticals and FORUM Pharmaceuticals. He received his post-doctoral training as an NIH NRSA Fellow at Harvard Medical School and holds a Ph.D. in Biomedical Engineering from the University of Rochester. read more...


What We Do

C4 Therapeutics is harnessing the innate power of the body to control the quality of proteins within cells. Our approach uses drugs to target disease-causing proteins for destruction. This breakthrough technology offers many advantages for the treatment of cancer and other diseases, while avoiding traditional drug resistance.

In June 2015, Jay Bradner, MD and co-workers at the Dana-Farber Cancer Institute, showed that derivatives of thalidomide could be used to target specific proteins for degradation. This ground breaking research, which began in 2011, is now being advanced toward clinical impact by C4 Therapeutics, which was founded in late 2015 by Dr Bradner, along with Ken Anderson, MD, Nathanael Gray PHD, and Marc Cohen.
At C4 Therapeutics, we are combining world-class expertise in medicinal chemistry, protein biochemistry, biophysics and structural biology with pharmacology and disease biology. Our approach - which is centered on the Degronimid™ platform - prizes innovative and collaborative science, both internally and externally.


Contact Us

PhmailiconTelephone:   +1  617 588 6114

Email:   C4 Therapeutics